Abstract:Cardiac fibrosis, the main pathological process from ventricular remodeling to heart failure, has attracted much more attention in recent years. Transforming growth factor beta-1 (TGF-β1) plays a key role in the pathogenesis of cardiac fibrosis. Bone morphogenetic protein 6 (BMP6), a member of the TGF-β family, is reportedly involved in many fibrosis-related diseases, such as hepatic and renal fibrosis. Nevertheless, there are few reports about the specific role of BMP6 in cardiac fibrosis. Here, we demonstrated the protein levels of BMP6 were lower in patients with heart failure. In addition, BMP6 expression appeared lower in left ventricles of rats in a transverse aortic constriction (TAC) surgery group compared with the sham group. Next, we observed that silencing BMP6 using small interfering RNA remarkably aggravated TGF-β1-induced cardiac fibrosis, while overexpression of BMP6 by Adenovirus largely improved cardiac fibrosis. Moreover, we found that BMP6 played a protective role in cardiac fibrosis via inhibiting the TGF-β1/Smad3 pathway, that partially functioned via interferon regulatory factor 7 (IRF7) suppression. Finally, we introduced Adeno-associated virus-9 (AAV-9) carrying shBMP6 and found that TAC surgery-induced cardiac fibrosis was significantly aggravated, while administration of rh-BMP6 via tail vein injection markedly ameliorated cardiac fibrosis induced by knockdown of BMP6 in vivo. In conclusion, our study demonstrated that BMP6 may serve as a novel biomarker and a therapeutic target in heart failure related to cardiac fibrosis. Funding Statement: This study was supported by the National Natural Science Foundation of China [No. 81770242 to YaChen Zhang] and Natural Science Foundation of Ningbo (No:2019A610388). Declaration of Interests: The authors declare that they have no conflicts of interest. Ethics Approval Statement: The collection and use of human LV samples were approved by the local human research ethics committee of Shanghai Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine Animal studies were approved by the Animal care and Use Committee of Shanghai Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine.

Bone morphogenetic protein-4: a novel therapeutic target for pathological cardiac hypertrophy/heart failure

Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy.

Bone morphogenetic protein-4 contributes to the down-regulation of Kv4.3 K+ channels in pathological cardiac hypertrophy.

Transforming growth factor-β and bone morphogenetic protein signaling pathways in pathological cardiac hypertrophy

Insights into bone morphogenetic proteins in cardiovascular diseases.

The Therapeutic Potential of BRD4 in Cardiovascular Disease

Role and Mechanism of BMP4 in Regenerative Medicine and Tissue Engineering

The Role of Bone Morphogenetic Protein 4 in Lung Diseases

Bone morphogenetic protein-2 antagonizes bone morphogenetic protein-4 induced cardiomyocyte hypertrophy and apoptosis.

Bone morphogenetic protein 10, a rising star in the field of diabetes and cardiovascular disease

[Progress in the Study on Bone Morphogenetic Protein 2/4 in Central Nervous System].

Bone Morphogenetic Protein-10 Induces Cardiomyocyte Proliferation and Improves Cardiac Function after Myocardial Infarction

Role and mechanism of BMP4 in bone, craniofacial, and tooth development

Bone Morphogenetic Protein-4 Induces Upregulation of Cav3.1 Ca 2+ Channels in HL-1 Atrial Myocytes

BMP10 preserves cardiac function through its dual activation of SMAD-mediated and STAT3-mediated pathways

Bone Morphogenetic Protein 6 Alleviates Cardiac Fibrosis and Dysfunction in Heart Failure

Targeting BMP signalling in cardiovascular disease and anaemia

Bone Morphogenetic Protein 10 Alleviates Doxorubicin-Induced Cardiac Injury Via Signal Transducer and Activator of Transcription 3 Signaling Pathway

BMP6 knockdown enhances cardiac fibrosis in a mouse myocardial infarction model by upregulating AP-1/CEMIP expression

Bone morphogenetic protein 4 in perivascular adipose tissue ameliorates hypertension through regulation of angiotensinogen

The effect of bone morphogenetic proteins in fibrotic diseases in ophthalmology